GlassScriptPhysician profile
Daivik Vyas
NPI 1508446410
$1,546.57
in general payments reported to CMS, 2019-2025
9 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $662 · 2024: $515 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $345.71 | 2023 | Pcm, Xlif |
| Stryker Corporation | $300.82 | 2023-2024 | Serrato, N/A |
| Globus Medical, INC. | $233.96 | 2024 | Creo Threaded |
| Medtronic, INC. | $183.71 | 2023-2025 | Stealthstation S8 Platform, Midas Rex |
| Si-Bone, INC. | $166.68 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $121.90 | 2022 | |
| Icotec Medical INC. | $86.50 | 2025 | Vader Pedicle System, Rod, Carbon/Peek, Curved, 6.0 R450 X 200 Mm, Vader Pedicle System 6.0, Screw, Carbon/Peek, Polyax., Fen., O 5.5 X 45 Mm, Kong-Tl Vbr, End Plate, Round, L and Screw, 12 X 43 Mm |
| Cerapedics INC. | $73.43 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Silk Road Medical, INC. | $33.86 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daivik Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.